This site is intended for health professionals only

Wednesday 16 October 2019
Share |

Topic: roche

October 12, 2018
The new unit will focus on digital diagnostics and help laboratories, hospitals and other healthcare providers to 'optimise' their performance

Lab solutions company Roche Diagnostics has launched a new business unit called Roche Healthcare Consulting. 
The new unit will focus on digital diagnostics and help laboratories, hospitals and other healthcare providers to “optimise their performance”.
The global consulting service will feature over 250 experienced consultants who specialise in business, healthcare and technology, and will use data analytics and reports to help clients improve their operational, clinical and financial performance.

March 1, 2018
Hemlibra is a bispecific monoclonal antibody, which was developed using Chugai’s proprietary antibody engineering technologies

Chugai has announced that Roche has received regulatory approval from the European Commission for Hemlibra® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors.

January 12, 2018
If licensed, ocrelizumab will be the first and only treatment option for adults in the European Union with primary progressive multiple sclerosis

Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of ocrelizumab for adults with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for adults with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

January 9, 2018
Partnership will apply advanced analytics to in vivo data from GE’s medical imaging and monitoring equipment with in vitro data from Roche’s biomarker, tissue pathology, genomics and sequencing portfolio

Roche has announced that it has entered into a strategic, long-term partnership with GE Healthcare in order to jointly develop and co-market digital clinical decision support solutions.

November 2, 2017
Patients with ‘forgotten cancer’ to access new immunotherapy Tecentriq® (atezolizumab) via Cancer Drugs Fund

The National Institute for Health and Care Excellence (NICE) has recommended the use of a new immunotherapy via the Cancer Drugs Fund.

September 14, 2017
University Hospitals Birmingham NHS Foundation Trust and Roche Diagnostics introduce pioneering approach to lung cancer diagnosis

A simple test which can detect gene mutations in tumour DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.

July 13, 2017
Emicizumab reduced treated bleed rate by 87% versus comparator in HAVEN 1 clinical study

Roche Products Ltd and Chugai Pharma UK Ltd have announced that data from HAVEN 1, a Phase III study of the investigational medicine emicizumab in people aged 12 or over with haemophilia A with inhibitors, were published online in The New England Journal of Medicine (NEJM).

October 10, 2016
Investigational immunotherapy atezolizumab first anti-PD-L1 antibody to extend overall survival compared with standard of care in NSCLC.

December 21, 2015
Additional tests support long-term routine management of organ transplant recipients and enhance the testing workflow in medical laboratories

Roche announced the market availability* of the new Elecsys® Sirolimus and Everolimus immunosuppressive drug assays. The launch of these two assays, which complement the currently available mycophenolic acid (MPA), Elecsys Tacrolimus and Cyclosporine assays, completes the Roche Diagnostics immunosuppressive drug monitoring portfolio.

November 25, 2015
Critical care providers can determine their patients’ coagulation status quickly and accurately, allowing them to make immediate, informed decisions

Roche announced that it has launched the CoaguChek Pro II system in countries accepting the CE Mark.1 CoaguChek Pro II combines two tests in a single device – the activated partial thromboplastin time (aPTT) test and the prothrombin time (PT) test with extended claims – for greater insight into patients’ coagulation status in acute care settings, such as emergency rooms, operating rooms and intensive care units, or anticoagulation clinics.

November 20, 2015
Roche announced that its new lab-coagulation solution, the cobas t 411 analyser, is now available for countries accepting the CE Mark

The new cobas t 411 analyser is a stand-alone lab coagulation system that is suitable for low-volume routine testing (up to 120 samples per day). With this launch, Roche has expanded their overall laboratory coagulation offering, giving laboratories further flexibility for their dedicated testing needs.

Main features of the cobas t 411 analyser include:

April 2, 2008
Roche Diagnostics has announced the global launch of an enhanced software (Version 7.0) for its flagship bloodgas analyser; the cobas b 221 system

Roche Diagnostics has announced the global launch of an enhanced software (Version 7.0) for its flagship bloodgas analyser; the cobas b 221 system.

The cobas b 221 is a desktop device designed for critical care providing bloodgas analysis, the measurement of the most important electrolytes, as well as glucose, lactate, urea, bilirubin and haemoglobin derivatives.